A new sequence of pyrazole derivatives (1–6) was synthesized from condensation technique under utilizing ultrasound irradiation. Synthesized compounds were characterized from IR, $^1$H NMR, $^{13}$C NMR, Mass and elemental analysis. Synthesized compounds (1–6) were screened for antimicrobial activity. Among the compounds 3 (MIC: 0.25 μg/mL) was exceedingly antibacterially active against gram negative bacteria of *Escherichia coli* and compound 4 (MIC: 0.25 μg/mL) was highly active against gram positive bacteria of *Streptococcus epidermidis* compared with standard Ciprofloxacin. Compound 2 (MIC: 1 μg/mL) was highly antifungal active against *Aspergillus niger* proportionate to Clotrimazole. Synthesized compounds (1–6) were screened for anti-inflammatory activity and the compound 2-((5-hydroxy-3-methyl-1H-pyrazol-4-yl)(4-nitrophenyl)methyl)hydrazinecarboxamide (4) was better activity against anti-inflammatory when compared with standard drugs (Diclofenac sodium). Compounds (2, 3 and 4) are the most important molecules and hence the need to develop new drugs of antibacterial, antifungal and anti-inflammatory agents.

**1. Introduction**

The pyrazole moiety is a versatile lead molecule in the pharmaceutical development and has a wide range of biological activities (Goda et al., 2003; El-Emary, 2006; Mansour et al., 2003), antibacterial (Sangapure et al., 2001), antifungal (Gupta et al., 2005; Ashish et al., 2006) and pharmacological activities such as anti-inflammatory (Makhsumov et al., 1986), antitubercular (Chetan and Mulwar, 2000), anticancer (Nimavat and Popat, 2007), analgesic (Udupi et al., 1998), antipyretic (Fabiane et al., 2002), anticonvulsant (Ashok et al., 2001) activities.

Commercially available pyrazole moiety (Fig. 1) such as Celecoxib is potent COX-2 inhibitor (Penning et al., 1997). Some other examples of pyrazole derivatives as NSAID are ramifinazone (Fioravanti et al., 2010), Lonazolae (NSAID)
(Riedel, 1981) and Rimonabant (Isidro and Cordido, 2009). Compound (phenylbutazone) is a non-steroidal drug (Reed et al., 1985; Vennerstorm et al., 1987). Pyrazofurin is potential of antiviral activity, HCV virus (Rostom et al., 2003; Riyadh et al., 2010; Popovici-Muller et al., 2009; Farghaly et al., 2011). In the current research, anti-inflammatory drug has been used in most prominent research areas. New anti-inflammatory drugs were previously used in clinical research, some of the drugs are still not efficient and have intolerable side effects.

Based on the above study, we need to develop new drugs against anti-inflammatory and antimicrobial activities. Therefore, we were led to identify new approaches of pyrazole derivatives as well as test the antimicrobial and anti-inflammatory activity.

2. Methods and materials

2.1. Chemicals and reagents

All chemicals were acquired from Sigma-Aldrich Chemical Co (Sigma–Aldrich Corp., St. Louis, MO, USA). The Infrared spectra (KBr), Proton NMR, Carbon NMR, Mass spectra (EI), and Elemental analysis (C, H, N and S) were recorded using Shimadzu 8201PC (4000–400 cm⁻¹), Bruker DRX-400 MHz, Jeol JMS D-300 spectrometer operating, and Elementer analyser model (Varian EL III).

2.1.1. Synthesis of 2-((5-hydroxy-3-methyl-1H-pyrazol-4-yl) (phenyl)methyl)hydrazinecarboxamide (1)

A mixture of 5-hydroxy-3-methyl-1H-pyrazoles (0.1 mol), benzaldehyde (0.1 mol) and semicarbazide hydrochloride (0.1 mol) was treated with ultrasound irradiation under ethanol medium. After completion of reaction, the product was isolated and identified by TLC. The identified product was separated from column chromatography and recrystallized by suitable solvent. The above experiential procedure was pursued by remaining compounds 2–6.

IR (cm⁻¹): 3445 (C–OH), 670(–CH–), 1679 (NH CO), 1569 (NH2).

1H NMR (DMSO-d6): δ 9.90 (s, 1H, C–OH), 2.71 (d, J = 4.4 Hz, 1H, CH), 2.23(s, 3H,CH3), 4.45 (dd, J = 5.3 Hz, 1H, –CH–), 7.33–7.49 (m, 5H, Phenyl ring), 2.36 (d, J = 2.0 Hz, 1H, NH), 6.81 (d, J = 1.4 Hz, 1H, NH), 6.25 (s, 2H, NH2). 13C NMR (CDCl3): δ 167.2(C–OH), 162.6 (C–CH3), 42.2(C–CH–), 52.3(C–CH–NH), 155.4(CONH2), 141.7, 112.0, 129.2, 133.8 (Phenyl ring).

Mass (m/z): 261.27 (M⁺, 32%), 244.28, 216.38, 200.27 (100%), 185.26, 170.25, 94.15.

2.1.2. 2-{(4-chlorophenyl)(3-hydroxy-5-methyl-4H-pyrazol-4-yl) methyl}hydrazinecarboxamide (2)

IR (cm⁻¹): 3469 (C–OH), 690(–CH–), 1679 (NH CO), 1554(NH2), 897(C–Cl). 1H NMR (DMSO-d6): δ 9.96 (s, 1H, C–OH), 2.76 (d, J = 4.3 Hz, 1H, CH), 2.23(s, 3H,CH3), 4.30(dd, J = 5.2 Hz, 1H, –CH–), 7.21–7.39 (dd, J = 1.4 Hz, 1H, NH), 2.67 (s, J = 2.1 Hz, 1H, NH), 6.73 (s, J = 1.6 Hz, 1H,
2.1.3. 2-(3-hydroxy-5-methyl-4H-pyrazol-4-yl)
(4-hydroxyphenyl)methyl)hydrazinecarboxamide (3)
IR(cm⁻¹): 3457 (C–OH), 1694 (C=O), 1671 (CONH₂).
¹³C NMR (CDCl₃): δ 167.1 (CO–), 156.3 (CONH₂),
144.7, 112.5, 128.2, 131.2 (Phenyl ring). Mass
(m/z): 295.72 (M+), 228.28, 200.27, 185.26.

2.1.4. 2-[3-hydroxy-5-methyl-4H-pyrazol-4-yl)
(4-nitrophenyl)methyl)hydrazinecarboxamide (4)
IR(cm⁻¹): 3460 (C–OH), 1688 (C=O), 1514 (CONH₂).
¹³C NMR (CDCl₃): δ 163.2 (C–OH), 155.4 (CONH₂),
146.7, 111.5, 128.2, 137.2 (Phenyl ring). Mass
(m/z): 277.27 (M+), 228.28, 200.27, 185.26.

Table 1. Physicochemical data of the compounds

| Compound | R1 | R2 | Molecular Formula | Molecular Weight |
|----------|----|----|------------------|-----------------|
| 3         | H  | H  | C₁₇H₁₇N₂O₂   | 295.72          |
| 4         | H  | NO₂| C₁₇H₁₇N₂O₂₃ | 306.27          |

2.2. Pharmacological activity

2.2.1. Anti-inflammatory activity

Isolated compounds (1-6) were evaluated by anti-
inflammatory activity, screening method followed from the lit-
erature method (Winter et al., 1962). Albino rats of both sexes
weighing 150 g were divided into 4 groups, each group consists
of 5 animals. Inflammation was induced by intra planter injec-
tion of histamine (0.1 mL of 1% histamine for induction of
paw edema). The rats are challenged by s.c injection of
0.1 mL of 1% solution of histamine into the sub-plantar side
of the left hind paw. 1 h after the administration of the test
compounds (10 mg/kg; p.o), one group was kept as control,
received only 0.5% carboxy methyl cellulose solution. The vol-
ume was measured before and after 3 h of carrageen treatment
by means of plethysmometer.

The percentage of anti-inflammatory activity was calcu-
lated by = (Vc – Vt/Vc) × 100. Vc = control, Vt = test
sample.

2.2.2. In vitro antibacterial screening

The antibacterial screening for isolated compounds was deter-
mined by the disc diffusion method (Bauer et al., 1996) using
Mueller–Hinton agar (Hi-Media) medium. The synthesized
compounds were evaluated against gram negative bacteria of
Escherichia coli (MTCC-739), Pseudomonas aeruginosa
(MTCC-2435), Klebsiella pneumonia (recultured) and gram
positive bacteria of Streptococcus epidermidis, Staphylococcus
aureus (MTCC-96). Synthesized compounds were initially
screened by maximum concentration at 100 μg/mL in
DMSO. The zone of inhibition was measured after 24 h incu-
bation at 37 °C. The MIC was identified by twofold dilutions
of the solution method (64, 32, ... , 0.5 μg/mL).

2.2.3. In vitro antifungal screening

The antifungal screening for isolated compounds was deter-
mined by using the disc diffusion method (Verma et al., 1998)
with Sabouraud’s dextrose agar (Hi-Media). The iso-
lated compounds were estimated for their in vitro antifungal activity against Aspergillus niger, Candida albicans,
Microsporum audouinii and Cryptococcus neoformans (recu-
tured). Synthesized compounds were initially screened by max-
imum concentration at 100 μg/mL in DMSO. The zone of
inhibition (mm) was measured after incubation at 37 °C. The
MIC was identified by twofold dilutions of the solution
method (64, 32, ... , 0.5 μg/mL).

3. Results

3.1. Synthesis and characterization of pyrazole analogues

Title compounds (1-6) were synthesized from 3-(3-hydroxy-
3(5)-methyl-1H-pyrazol-4-yl)methyl)hydrazinecarboxamide via Ultrasound irradiation under aqueous medium and without catalysts. The synthetic route of pyrazole
derivatives is represented in Scheme 1. The compounds (1-6) were manufactured by Mannich base condensation method and the mechanism of the work outlined in Scheme 1. Physicochemical data of the compounds (1-6) are given in Table 1.
Isolated compounds were characterized by Infra red, Proton NMR, Carbon NMR spectrum, Mass spectra, and elemental analyses.

Compound 1 was confirmed by IR spectral analysis, which indicates the value of 3445 cm⁻¹/C0₁ corresponding to the OH group nearby in the pyrazole ring and another absorption band at 670 cm⁻¹/C0₁ corresponding to the –CH– group presented in the pyrazole ring. Another analysis of ¹H NMR spectrum shows the signals observed at δ 13.03, 11.43, 5.45, 2.36, and 6.25 corresponding to NH in the pyrazole ring, C–OH, –CH–, NH, CH, and NH₂ protons respectively and ¹³C NMR spectrum shows that peaks at δ 132.2, 51.2, and 12.7 correspond to C–OH, C–CH–NH, and CH₃ carbons respectively. Molecular mass of compound 1 was confirmed by mass spectral analysis, which is indicated that the molecular ion peaks at 261.27(M⁺, 32%).

3.2. Anti-inflammatory activity

Isolated products (1–6) were evaluated for anti-inflammatory activity match up with diclofenac sodium at oral dose. Rat albino was used as an oral dose of the test compound at a concentration of 10 mg/kg, the percentage of the activity was measured at 3 h. Compound (4) is highly active compared with standard. Fig. 2 shows the activity difference of compounds (1–6), anti-inflammatory activity records are presented in Table 2.

3.3. Antibacterial activity

Compound (3) is exceedingly active (MIC: 0.25 µg/mL) against gram negative bacteria of E. coli compared with Ciprofloxacin MIC: 0.5 µg/mL. Compound (4) (MIC: 0.25 µg/mL) is highly active and match up with standard (MIC: 4 µg/mL) against gram-negative bacteria of S. epidermidis. The bacterial zones of inhibition values are presented in Table 3 and Fig. 3 indicates differentiation of antibacterial activity in isolated compounds (1–6).

3.4. Antifungal activity

Compound (2) MIC: 1 µg/mL is greatly active against A. niger match up to with Clotrimazole MIC: 2 µg/mL. Compound (3) (MIC: 0.5 µg/mL) has equipotent activity against M. audouinii match up to with standard Clotrimazole (MIC: 0.5 µg/mL) whereas compound 5 (MIC: 4 µg/mL) is moderately active against A. niger. The fungal zones of inhibition values are presented in Table 4. Fig. 4 indicates differentiation of antifungal activity in isolated compounds of compounds (1–6). Minimal inhibitory concentration (MIC) data are reported in Table 5.

3.5. Structure–activity relationship

The anti-inflammatory and antimicrobial performances of the isolated compounds were confirmed by structure–activity relationships (Fig. 5).

The 4-substituted phenyl ring with semicarbazone acts as a lipophilic and hydrogen bonding domain. Therefore, the above group containing the pyrazole ring may be stated as the essential pharmacophoric requirement for anti-inflammatory activity.

(i) Compound 3 (MIC: 0.25 µg/mL) pyrazole derivative exhibited high activity against gram negative E. coli compared with standard Ciprofloxacin and also antifungal activity of compound 3 exhibited equipotent activity (MIC: 0.5 µg/mL) against M. audouinii match up to with standard Clotrimazole.
(MIC: 0.5 µg/mL), reason of activity due to the presence of 4-OH-phenyl with semicarbazone and pyrazole moiety in compound 3. (ii) Compound 2 (MIC: 1 µg/mL) is highly active against gram negative bacteria of *K. pneumoniae* and also highly active (MIC: 1 µg/mL) against *A. niger* compared with standard Clotrimazole (MIC: 2 µg/mL) in antifungal screening. 4-Cl-phenyl with semicarbazone and pyrazole moiety were represented to be highly active against *K. pneumoniae* bacterial and *A. niger* fungal strain. (iii) Compound 4 is highly active (MIC: 4 µg/mL) against gram positive bacteria of *S. epidermidis* compared with standard Ciprofloxacin (MIC: 4 µg/mL), reason of activity due to the presence of 4-NO2-phenyl with semicarbazone and pyrazole moiety in compound 4. The compound 4 is very much active (82%) against anti-inflammatory in relation to Diclofenac sodium 74.0% of activity.

### Table 2: Anti-inflammatory activity of compounds (1–6).

| Comp. No | Increase in paw volume (3hr – 0hr) | Percentage (%) of Activity, Dose (10 mg/ kg) |
|----------|-------------------------------------|-----------------------------------------------|
| Control  | 0.56                                | –                                             |
| 1        | 0.22 ± 0.05                         | 66.0*                                         |
| 2        | 0.18 ± 0.06                         | 67.8*                                         |
| 3        | 0.32 ± 0.06                         | 42.8*                                         |
| 4        | 0.10 ± 0.02                         | 82.1*                                         |
| 5        | 0.38 ± 0.09                         | 32.1*                                         |
| 6        | 0.41 ± 0.02                         | 26.7*                                         |
| Standard | 0.14 ± 0.01                         | 75.0*                                         |

Mean ± SEM, *n* = 6 in each group. Significance levels *P* < 0.01 as compared with the respective control. Diclofenac sodium was used as a standard.

### Table 3: Antibacterial activity of isolated products (1–6).

| Compounds | Gram-negative | Gram-positive |
|-----------|---------------|---------------|
|           | *E. coli* | *P. aeruginosa* | *K. pneumoniae* | *S. aureus* | *S. epidermidis* |
| 1         | 12      | –               | –               | –           | 12              |
| 2         | 16      | –               | –               | 18          | 16              |
| 3         | 28      | 8               | –               | –           | 10              |
| 4         | 20      | –               | 8               | 12          | 18              |
| 5         | 18      | 12              | 10              | –           | 12              |
| 6         | 15      | –               | –               | 14          | 14              |
| Standard  | 26      | 17              | 19              | 22          | 15              |

Ciprofloxacin used as a standard, zone of inhibition measured at (mm).
Table 4  Antifungal activity of isolated products (1–6).

| Compounds | A. niger | C. albicans | C. neoformans | M. audouinii |
|-----------|---------|-------------|---------------|-------------|
| 1         | 10      | –           | –             | 12          |
| 2         | 24      | 12          | –             | 18          |
| 3         | 15      | 16          | 8             | 25          |
| 4         | 14      | 10          | –             | 10          |
| 5         | 20      | 12          | 10            | 12          |
| 6         | 18      | –           | –             | 10          |
| Standard  | 22      | 24          | 25            | 26          |

Clotrimazole used as a standard, zone of inhibition measured at (mm).

Table 5  Minimum inhibition concentration of isolated products (2, 3 and 5).

| Comp. No. | E. c | P. a | K. p | S. a | S. e | A. n | C. a | C. n | M. a |
|-----------|------|------|------|------|------|------|------|------|------|
| 2         | 64   | >100 | 1    | >100 | 16   | 1    | 64   | >100 | 16   |
| 3         | 0.25 | 64   | >100 | 64   | 64   | 64   | 64   | >100 | 0.5  |
| 4         | 16   | >100 | >100 | 64   | 2    | 64   | >100 | >100 | >100 |
| 5         | 16   | 32   | 64   | >100 | 16   | 4    | 64   | 64   | 32   |
| Ciprofloxacin | 0.5 | 1    | 2    | 0.5  | 4    | –    | –    | –    | –    |
| Clotrimazole  | –   | –    | –    | –    | –    | 2    | 1    | 0.5  | 0.5  |

Figure 4  Antifungal activity of compounds (1–6).

Figure 5  Structure–activity relationships for compounds (3, 2 and 4).
5. Conclusion

In conclusion, synthesized compounds (1–6) were tested with anti-inflammatory and antimicrobial screening. Among the series, compound (3) (MIC : 0.25 µg/mL) was found to be the most active against gram negative bacterial strain *E. coli* compared with the most standard Ciprofloxacin, antifungal activity of compound (2) (MIC : 1 µg/mL) was greatly active against *A. niger* than standard Clotrimazole and compound (4) showed better activity against anti-inflammatory when compared with Dichlofenac sodium. Therefore these derivatives could provide as a highly momentous molecule for further development of antimicrobial, anti-inflammatory agents.

Acknowledgment

We are very grateful to Saudi Biological Society and Prince Sultan Research Chair for Environment and Wildlife, Department of Botany & Microbiology, College of Sciences, King Saud University (KSU), Riyadh, Saudi Arabia for encouragement and support.

References

Ashish, K.T., Anil, M., Verma, H.N., Mishra, A., 2006. Synthesis and antifungal activity of 4-substituted-3,7-dimethyl pyrazolo[3,4-e] [1,2,4] triazine. Ind. J. Chem. 45B, 489–492.

Ashok, K., Archana, Sharma, S., 2001. Synthesis of potential quinazolinyl pyrazolines as anticonvulsant agents. Ind. J. Hetero. Chem. 9, 197.

Bauer, A.W., Kirby, W.M., Sherris, J.C., Turck, M., 1996. Antibiotic susceptibility testing by a standardized single disk method. Am. J. Clin. Pathol. 39 (5), 493–496.

Chetan, B.P., Mulwar, V.V., 2000. Synthesis and evaluation of certain pyrazolines and related compounds for their anti tubercular, anti bacterial and anti fungal activities. Ind. J. Chem. 44B, 222–237.

El-Emary, T.I., 2006. Synthesis and biological activity of some new pyrazole[3,4-b]pyrazines. J. Chin. Chem. Soc. 53, 391–401.

Fabiane, R.S., Vanessa, T.S., Viviane, R., Lysandro, P.B., Marli, R.O., Helio, G.B., Nilo, Z., Marcos, A.P.M., Carlos, F.M., 2002. Hypothermic and antipyretic effects of 3-methyl- and 3-phenyl-5-hydroxy-5- trichloromethyl-4,5-dihydro-1H-pyrazole-1-carboxamides in mice. Eur. J. Pharmacol. 451, 141–147.

Farghaly, T.A., Abass, I.M., Abdalla, M.M., Mahgoub, R.O.A., 2011. Synthesis and pharmacological activities of fused pyrimidinones. World J. Chem. 6, 8–18.

Fioreavanti, R., Bolasco, A., Manna, F., Rossi, F., Orallo, F., Ortuso, F., Alcaro, S., Cirilli, R., 2010. Synthesis and biological evaluation of N-substituted-3,5-diphenyl-2-pyrazoline derivatives as cyclooxygenase (COX-2) inhibitors. Eur. J. Med. Chem. 45, 6135–6138.

God, F.E., Maarouf, A.R., El-Bendary, E.R., 2003. Synthesis and antimicrobial evaluation of new isoxazole and pyrazole. Saudi Pharm. J. 11, 111–117.

Gupta, U., Sareen, V., Khatri, V., Chug, S., 2005. Synthesis and antifungal activity of new fluorine containing 4-pyrazole and isoxazole. Ind. J. Heterocycl. Chem. 14, 265–266.

Isidro, M.L., Cordido, F., 2009. Drug treatment of obesity: established and emerging therapies. Mini Rev. Med. Chem. 9, 664–673.

Makhsunov, A.D., Dzhuraev, Kiliqchov G., Nibkae, A.T., 1986. Anti-inflammatory Activity of some pyrazole derivatives. Pharm. Chem. J. 20, 289–291.

Mansour, A.K., Eid, M.M., Khalil, S.A.M.N., 2003. Synthesis and reactions of some new heterocyclic carboxyhydrates and related compounds as potential anticancer agents. Molecules 8, 744–755.

Nimavat, K.S., Popat, K.H., 2007. Synthesis anticancer, anti tubercular and antimicrobial activities of 1- substituted, 3-aryl-5(3’-bromophenyl) pyrazoline. Ind. J. Heterocycl. Chem. 16, 333–336.

Penning, T.D., Penning, T.D., Talley, J.J., Bentershaw, S.R., Carter, J.S., Collins, P.W., Docter, S., Graneto, M.J., Lee, L.F., Malecha, J.W., Miyashiro, J.M., Rogers, R.S., Rogier, D.J., Yu, S.S., Anderson, G.D., Burton, E.G., Cogburn, J.N., Gregory, S.A., Koboldt, C.M., Perkins, W.E., Seibert, K., Veenhuizen, A.W., Zhang, Y.Y., Isakson, P.C., 1997. Synthesis and biological evaluation of the 1,5-diaryl/3pyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulphonamide (SC-58635, celecoxib). J. Med. Chem. 40, 1347–1365.

Popovic-Muller, J., Shipps Jr., G.W., Rosner, K.E., Deng, Y., Wang, T., Curran, P.J., Brown, M.A., Siddiqui, M.A., Cooper, A.B., Duca, J., 2009. Pyrazole[1,5-alpyrimidine-based inhibitors of HCV polymerase. Bioorg. Med. Chem. 19, 6331–6336.

Reed, G.A., Griffin, I.O., Eling, T.E., 1985. Inactivation of prosta glandin H synthase and prostacyclin syntheses by phenylbutazone. Requirement for peroxidative metabolism. Mol. Pharmacol. 27, 109–114.

Riedel, R., 1981. Lonoazolac-Ca = Calcium [3-(p-chlorophenyl)-1 phenylpyrazole-4-acetate 1 Pharmacological properties of a new antiinflammatory/antirheumatic drug (author's transl). Arzneimittelforschung 31, 655–665.

Riyadh, S.M., Faraglhy, T.A., Abdallah, M.A., Abdalla, M.M., Abd El-Aziz, M.R., 2010. New pyrazoles incorporating pyrazolylpyrazole moiety. Synthesis, anti-HCV and antitumor activity. Eur. J. Med. Chem. 45, 1042–1050.

Rostom, S.A., Shalaby, M.A., El-Demellawy, M.A., 2003. Polysubstituted pyrazoles, part 5. Synthesis of new 1-(4-chloro phenyl)-4-hydroxy-1H-pyrazole-3-carboxylic acid hydrazide analogs and some derived ring systems. A novel class of potential antitumor and anti-HCV agents. Eur. J. Med. Chem. 38, 959–974.

Sangapure, S.S., Bodke, Y., Raga, B., 2001. Synthesis of some new pyrazolines as potential antimalarial agents. Ind. J. Heterocycl. Chem. 11, 31–37.

Udupi, R.H., Bhat, A.R., Krishna, K., 1998. Synthesis and investigation of some new pyrazoline derivatives for their antimalarial, anti inflammatory and analgesic activities. Ind. J. Heterocycl. Chem. 8, 143–146.

Vennerstrom, J.L., Holmes Jr., T.J., 1987. Preparation and evaluation of electrophilic derivatives of phenylbutazone as inhibitors of prostaglandin-H-synthase. J. Med. Chem. 30, 563–567.

Verma, R.S., Khan, I.K., Singh, A.P., 1998. Antifungal agents, past, present, future prospects, National Academy of Chemistry and Biology, Lucknow, India. pp. 55–128.

Winter, C.A., Risley, E.A., Nuss, G.N., 1962. Carrageeninduced edema in hind paw of the rat as an assay for antiinflammatory drugs. Proc. Soc. Exp. Biol. Med. 111, 544–547.